Overview
AOD-9604 is a 16-amino-acid modified fragment of human growth hormone, derived from the C-terminal lipolytic region often described around hGH 176-191 or 177-191. It has molecular mass about 1,815 g/mol and formula C78H123N23O22S2. It was developed as an anti-obesity candidate intended to separate fat-metabolism signaling from the growth-promoting and IGF-1 effects of full-length growth hormone.
Mechanistically, AOD-9604 has been studied for effects on lipolysis, fat oxidation, and beta-3 adrenergic receptor-related pathways in obese animal models. The appeal is easy to understand: a GH-derived fragment that might influence fat handling without acting like full GH. The problem is that promising animal work did not translate into a clearly successful obesity drug program.
AOD-9604 is not FDA-approved for weight loss, body recomposition, or any medical indication. It has appeared in sports-doping discussions and analytical detection literature, which matters for competitive athletes. Published human safety work exists, but clinical efficacy has not supported routine therapeutic use, and commercial peptide products vary in quality.
This guide focuses on what is actually known: the beta-3 adrenergic findings, the limits of human obesity trials, practical safety concerns, dosing uncertainty, and why AOD-9604 should be framed as investigational rather than a proven fat-loss tool.
Quick facts
- Mechanism
- Modified hGH C-terminal fragment studied for lipolysis without GH receptor effects
- Primary use
- Fat Metabolism Research
- Evidence
- moderate
- FDA
- Not approved
- Route
- Subcutaneous or oral research protocols
- Typical results
- Modest or inconsistent fat-mass effects; stronger animal than human evidence
Chemical information
AOD-9604 is a disulfide-containing peptide fragment with formula C78H123N23O22S2 and molecular mass about 1,815 g/mol. It is modified from the C-terminal region of human growth hormone and is much smaller than intact hGH.
How AOD-9604 works
AOD-9604 is designed to mimic a lipolytic region of growth hormone while avoiding the broader GH receptor actions that raise IGF-1 and affect growth, glucose handling, and fluid balance. In animal studies, chronic exposure altered beta-3 adrenergic receptor expression and fat metabolism. Human translation remains uncertain, so mechanism claims should stay narrow.
The best-known preclinical work showed that AOD-9604 and human GH reduced body weight and fat in obese mice, with changes linked to beta-3 adrenergic receptor expression in adipose tissue. In beta-3 receptor knockout mice, chronic lipolytic and weight effects were blunted, suggesting that the pathway is important for sustained effects. Acute energy-expenditure changes may involve additional mechanisms.
Unlike full-length GH, AOD-9604 was intended not to stimulate linear growth, organ growth, or IGF-1 elevation. That separation is the central scientific rationale. However, a plausible mechanism is not the same as clinically meaningful weight loss. Human studies and development history suggest that any effect is likely subtle and dependent on energy balance rather than a stand-alone fat-loss intervention.
From a peptide-user perspective, AOD-9604 is often stacked with GLP-1 agents, GH secretagogues, or exercise programs, but those combinations are not well studied. The mechanism does not justify assuming synergy, spot reduction, or protection from metabolic side effects.
- hGH fragment design: Uses the C-terminal lipolytic region rather than full growth hormone
- Beta-3 signaling: Animal data link chronic effects to beta-3 adrenergic receptor pathways
- Lipolysis support: Studied for release and handling of stored triglycerides
- Low IGF-1 intent: Developed to avoid classic GH growth-factor activation
- Clinical uncertainty: Human obesity results were not strong enough for approval
- Doping relevance: Detection methods exist and athletes should treat it as high risk
Pharmacokinetics
Human pharmacokinetic details for commercial AOD-9604 use are limited. Published work includes safety and metabolism studies, but routine user claims about half-life, oral bioavailability, or ideal timing should be treated cautiously unless tied to a specific study formulation.
| Parameter | Value | Significance |
|---|---|---|
| Human PK | Limited published data | No robust clinical-use PK guidance exists |
| Route studied | Oral and parenteral formulations reported | Formulation affects exposure and cannot be generalized |
| Half-life | Not confidently established for user products | Avoid precise timing claims without formulation data |
| Metabolism | Peptide degradation | Expected proteolytic breakdown into smaller fragments |
| Hormonal effects | Designed to avoid IGF-1 stimulation | Still requires monitoring in research contexts |
| Detection | Analytical LC-MS methods published | Relevant to anti-doping and product verification |
Dosing & administration
No FDA-approved AOD-9604 dose exists. Human studies used specific investigational formulations and protocols, but those do not validate the wide range of community peptide schedules used for body recomposition. Copying informal doses is not the same as evidence-based medicine.
Research and wellness-market protocols commonly discuss subcutaneous or oral use, but product identity, peptide content, and stability vary. The most conservative interpretation is that AOD-9604 may be studied as a metabolic adjunct, not relied on as a primary weight-loss therapy.
People using diabetes, obesity, thyroid, stimulant, or GH-axis drugs require particular caution. Any study design should define baseline metabolic markers, body composition methods, diet control, and adverse-event tracking, because scale changes alone cannot identify an AOD-specific effect.
Important: These dosing ranges are not FDA-approved. Any use should be under qualified medical supervision.
Side effects & safety
Published human safety data are more reassuring than efficacy data, but AOD-9604 remains investigational and unapproved. The biggest practical risks are unrealistic expectations, unregulated supply, unknown formulation quality, and stacking with stronger metabolic agents.
Common
- • Injection site irritation
- • Headache
- • Nausea or mild stomach discomfort
- • Fatigue
- • Water retention reported anecdotally
- • No noticeable effect despite use
Serious / potential risks
- • Unknown long-term safety with repeated nonmedical use
- • Contamination or mislabeling from unregulated peptide suppliers
- • Potential metabolic effects in vulnerable users despite limited data
- • Sports anti-doping violation risk
- • Unsafe stacking with other metabolic drugs
Drug interactions
Formal interaction studies are sparse; interaction concerns are based on metabolic context, co-administered weight-loss agents, and peptide-supply uncertainty.
| Medication | Interaction | Recommendation |
|---|---|---|
| GLP-1 receptor agonists | Unstudied combination for body composition | Monitor weight, intake, hydration, and adverse effects under supervision |
| Growth hormone or GH secretagogues | May confound GH-axis and IGF-1 interpretation | Avoid stacking in uncontrolled self-experiments |
| Insulin or sulfonylureas | Changing intake or fat loss can alter glucose needs | Medical monitoring is required |
| Stimulant weight-loss drugs | May increase cardiovascular strain when combined with aggressive dieting | Use caution and track blood pressure and heart rate |
| Competitive sport drug testing | May trigger anti-doping concerns | Athletes should avoid unless cleared by governing bodies |
Storage & handling
Lyophilized (powder)
- • Store at -20°C to 4°C (freezer or refrigerator)
- • Protect from light and moisture
- • Stable for 12–24 months when stored properly
- • Keep in original sealed container until reconstitution
Reconstituted solution
- • Refrigerate at 2–8°C after reconstitution
- • Use bacteriostatic water for multi-dose reconstitution
- • Typical stability: 14–28 days refrigerated
- • Do not freeze reconstituted solution
Cost & availability
| Source | Cost | Notes |
|---|---|---|
| Research peptide suppliers | $40-$120 per 5 mg vial | Quality and actual content vary widely |
| Wellness clinics | $200-$500 per month | Often sold in body-composition packages |
| Analytical testing | $150-$500+ per sample | Useful for identity and purity confirmation |
| Oral products | $50-$150 per month | Bioavailability depends on formulation |
The bottom line
AOD-9604 is a biologically interesting hGH fragment with credible animal data and limited human safety data, but it is not a proven or FDA-approved fat-loss drug. Any benefits are likely modest, and the quality of commercial peptide products is a major variable.
Best for
- • Researchers studying GH-fragment effects on lipid metabolism
- • Analytical labs validating AOD-9604 detection
- • Clinicians reviewing investigational body-composition claims
Not for
- • Expecting dramatic weight loss without diet control
- • Competitive athletes subject to anti-doping rules
- • Users stacking multiple metabolic drugs without supervision
- • Anyone relying on untested peptide sources
Related compounds
Acetic Acid
Related entry from the same enrichment batch for comparison of evidence, handling, and user-safety context.
Amino Tadalafil
Related entry from the same enrichment batch for comparison of evidence, handling, and user-safety context.
Astressin-B
Related entry from the same enrichment batch for comparison of evidence, handling, and user-safety context.
B7-33
Related entry from the same enrichment batch for comparison of evidence, handling, and user-safety context.
Frequently asked questions
References
- [1] Heffernan MA, Summers RJ, Thorburn A, Ogru E, Gianello R. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice. Endocrinology (2001). PMID: 11713213
- [2] Cox HD, Smeal SJ, Hughes CM, Cox JE, Eichner D. Detection and in vitro metabolism of AOD9604. Drug Testing and Analysis (2015). PMID: 25208511
- [3] Stier H, Vos E, Kenley D. Safety and metabolism of AOD9604, a novel nutraceutical ingredient for improved metabolic health. Journal of Endocrinology and Metabolism (2013).
- [4] Valentino MA, Lin JE, Waldman SA. Central and peripheral molecular targets for antiobesity pharmacotherapy. Clinical Pharmacology & Therapeutics (2010).
- [5] Thevis M, Thomas A, Schanzer W. Detecting peptidic drugs, drug candidates and analogs in sports doping: current status and future directions. Expert Review of Proteomics (2014). PMID: 24617318
- [6] National Center for Biotechnology Information. PubChem Compound Summary for AOD9604. PubChem (2026).